Tesamorelin Compounding Access After FDA Panel Endorses 6 Peptides
FDA panel endorses tesamorelin for 503A compounding, opening off-label obesity and alcohol use disorder research. Cost, safety, and regulatory
Read more →PINCOURT JOURNAL
News
Semaglutide Microdosing vs FDA Scrutiny: Off-Label GLP-1 Trends Under Fire
Semaglutide microdosing for off-label uses like cognition and longevity is gaining traction, but FDA warnings and media scrutiny highlight safety and
Read more →Tesamorelin Compounding Guidance Update: FDA Warning on GLP-1 Drugs May Impact GHRH Analog Oversight
FDA's crackdown on compounded semaglutide signals tighter oversight for GHRH analogs like tesamorelin. Compounders face scrutiny over sourcing and
Read more →Tesamorelin Boom Risk: FDA Panel Vote Fuels Safety vs. Access Debate
An FDA advisory panel vote intensifies the debate over compounded tesamorelin for visceral fat reduction. Safety concerns clash with access as demand
Read more →Tesamorelin Compounding Safety: New FDA Guidance on Peptide GHRH Analogs and Impurity Risks
New FDA guidance on compounded tesamorelin tightens impurity limits for GHRH analogs. 503A and 503B pharmacies face higher testing costs and
Read more →Compounded Semaglutide vs FDA Oversight: Telehealth Prescribers on Notice
A MedPage Today investigation found lax prescribing and quality issues with compounded semaglutide from telehealth platforms, putting prescribers on
Read more →